The United Kingdom Multiple Sclerosis Register Covid-19 Substudy
NCT04354519 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 3000
Last updated 2021-08-17
Summary
The aim of the study is to understand the impact of COVID-19 on People with Multiple Sclerosis in the United Kingdom.
Conditions
Sponsors & Collaborators
-
Swansea University
lead OTHER
Principal Investigators
-
Richard S Nicholas · Clinical Lead
-
Nikos Evangelou · Co-PI
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2020-03-14
- Primary Completion
- 2022-07-14
- Completion
- 2022-07-14
Countries
- United Kingdom
Study Locations
More Related Trials
-
Estimating Prevalence of COVID-19 Infection and SARS-CoV-2 Antibodies in MS Patients
NCT04682548 ·Status: COMPLETED
-
Epidemiological Characteristics of COVID-19 in Patients With MS or NMO
NCT04355611 ·Status: COMPLETED
-
Protection Against Severe Coronavirus Disease 2019 in Patients With Multiple Sclerosis Stratified According to Disease Modifying Treatment
NCT05834335 ·Status: COMPLETED
-
Regulation of Lipid Metabolism in Autoimmune Disease: Multiple Sclerosis
NCT04053374 ·Status: UNKNOWN
-
A Cross-Sectional Study of MSDx Complex 1 as a Marker for Active Disease in Multiple Sclerosis
NCT01539395 ·Status: WITHDRAWN
-
Investigation of Fatigue, Physical Activity, Sleep Quality and Anxiety Levels
NCT04438954 ·Status: COMPLETED
-
COVID-19 Vaccine Biomarker Study in Multiple Sclerosis
NCT05121662 ·Status: COMPLETED
-
MS PATHS COVID-19 Questionnaire Data Linkage Sub-Study
NCT05058729 ·Status: COMPLETED
-
Effect of Disease Modifying Therapy on Antibody Response to COVID19 Vaccination in Multiple Sclerosis
NCT04834401 ·Status: COMPLETED
-
Study of Empathy in MS
NCT05332951 ·Status: COMPLETED
-
Efficacy of COVID-19 Vaccination in Patients With Multiple Sclerosis Treated With Immune Modulating Medication
NCT04796584 ·Status: TERMINATED
-
A Study to Assess the Potential Impact of Disease Modifying Therapies on COVID-19 Outcomes and the Antibody Response Following an Infection With SARS-CoV-2 in Patients With Multiple Sclerosis Within the Swiss Multiple Sclerosis Cohort.
NCT04760990 ·Status: COMPLETED
-
A Study to Assess COVID-19 Vaccination Immune Response in Multiple Sclerosis Patients Treated With Ofatumumab
NCT06460324 ·Status: COMPLETED
-
Development of a Novel Functional Eye-Tracking Software Application for Multiple Sclerosis
NCT05061953 ·Status: RECRUITING
-
COVID-19 Booster Vaccination in Persons With Multiple Sclerosis
NCT05081271 ·Status: TERMINATED ·Phase: EARLY_PHASE1
-
CorEvitas Multiple Sclerosis (MS) Registry
NCT03291756 ·Status: ENROLLING_BY_INVITATION
-
Prevalence and Impact of Obstructive Sleep Apnea in Multiple Sclerosis
NCT04603196 ·Status: RECRUITING
-
Bladder Management in Patients With Multiple Sclerosis: Optimizing Practice Patterns
NCT01930799 ·Status: COMPLETED ·Phase: PHASE4
-
Prescription Drug Safety and Effectiveness in Multiple Sclerosis
NCT04472975 ·Status: COMPLETED
-
MicroRNA-150 and microRNA-155 in Multiple Sclerosis
NCT04300543 ·Status: UNKNOWN
-
Self Help for Fatigue in Multiple Sclerosis
NCT01532037 ·Status: COMPLETED ·Phase: NA
-
Pathogenicity of B and CD4 T Cell Subsets in Multiple Sclerosis
NCT04798651 ·Status: RECRUITING ·Phase: NA
-
Immunologic Biomarker Profile of Cerebrospinal Fluid
NCT04202055 ·Status: COMPLETED
-
The MURDOCK Study Community Registry and Biorepository Multiple Sclerosis Cohort
NCT01723709 ·Status: COMPLETED
-
From Genetics to Transcriptomics to Unravel the Mechanisms Behind a Poor Outcome in Multiple Sclerosis
NCT04873492 ·Status: RECRUITING ·Phase: NA